Fox Chase Cancer Center News

PHILADELPHIA (October 10, 2024) — TREX1, a gene previously associated with autoimmune diseases, has been linked to small cell lung cancer. The discovery by Fox Chase Cancer Center scientists is a step toward understanding why this aggressive cancer is so resistant to treatment.

“We don’t think it’s the same thing,” said Wei, who conducted the study with colleagues from Fox Chase and researchers from other institutions. “The molecular alteration is different, the morphology is different, and the clinical behavior is different. It’s a different tumor.”

PHILADELPHIA (October 8, 2024) — Daniel J. Campbell, TBE, CHFM, FASHE, Regulatory Compliance Officer at Fox Chase Cancer Center, received the Crystal Eagle Leadership Award from the American Society for Healthcare Engineering (ASHE), which represents professionals who design, build, and operate hospitals and other healthcare facilities.

PHILADELPHIA (October 1, 2024) — Thomas J. Galloway, MD, Chief of the Division of Head and Neck Radiation Oncology at Fox Chase Cancer Center, was today named a Fellow of the American Society for Radiation Oncology (ASTRO) at its 66th Annual Meeting in Washington, D.C.

PHILADELPHIA (September 30, 2024) — Using CT-guided online adaptive radiation therapy (ART) for patients with liver tumors has proven to be an effective approach, according to findings presented today by Fox Chase Cancer Center researchers at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Washington, D.C.

PHILADELPHIA (September 30, 2024)—Eric Horwitz, MD, FABS, FASTRO, Chair of the Department of Radiation Oncology at Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University, was elected to the Executive Committee of the Society of Chairs of Academic Radiation Oncology Programs (SCAROP), part of the American Society of Radiation Oncology (ASTRO).

PHILADELPHIA (September 30, 2024) — Online adaptive radiation therapy (ART) delivered radiation more effectively than conventional radiation therapy in nearly half of patients, while also helping to decrease radiation dose to the esophagus in a majority of patients with thoracic spine tumors. That’s according to the results of a study presented today by Fox Chase Cancer Center researchers at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Washington, D.C.

PHILADELPHIA (September 30, 2024) — Fox Chase Cancer Center physicians and scientists will participate in the presentation and discussion of nine research projects at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting, which is being held in Washington, D.C., from September 29 through October 2.